High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity

Stephanie K. Doerner¹, Edimara S. Reis², Elaine S. Leung³, Justine S. Ko¹, Jason D. Heaney⁴,⁵, Nathan A. Berger¹,⁶, John D. Lambris², and Joseph H. Nadeau¹,³

Abstract

Obesity and related metabolic disturbances are closely associated with pathologies that represent a significant burden to global health. Epidemiological and molecular evidence links obesity and metabolic status with inflammation and increased risk of cancer. Here, using a mouse model of intestinal neoplasia and strains that are susceptible or resistant to diet-induced obesity, it is demonstrated that high-fat diet-induced inflammation, rather than obesity or metabolic status, is associated with increased intestinal neoplasia. The complement fragment C5a acts as the trigger for inflammation and intestinal tumorigenesis. High-fat diet induces complement activation and generation of C5a, which in turn induces the production of proinflammatory cytokines and expression of proto-oncogenes. Pharmacological and genetic targeting of the C5a receptor reduced both inflammation and intestinal polyposis, suggesting the use of complement inhibitors for preventing diet-induced neoplasia.

Implications: This study characterizes the relations between diet and metabolic conditions on risk for a common cancer and identifies complement activation as a novel target for cancer prevention. Mol Cancer Res; 1–13. ©2016 AACR.

Introduction

Obesity is an increasingly important risk factor for many cancers (1, 2). Although the mechanisms underlying the association between obesity and cancer are not fully understood, hormonal changes and chronic inflammation support a favorable environment for tumor progression (1, 2). Alterations in adipose tissue that occur in response to excess nutrient intake lead to an imbalance between adipokines that are associated with insulin resistance and a proinflammatory environment that characterizes metabolic syndrome. Whereas leptin potentiates tumor growth through induction of cell proliferation, angiogenesis and inflammation, adiponectin has anti-inflammatory properties and is negatively correlated with body mass index (BMI; ref. 3). In colorectal cancer, imbalances in insulin and adipokine metabolism are associated with oxidative stress and increased levels of proinflammatory cytokines (3, 4).

Supporting a role for diet-induced obesity (DIO) in promoting inflammation and cancer, levels of IL6 and tumor burden are both reduced following azoxymethane treatment of obese Lepob/Lepob mice fed a bean-based diet versus a standard diet (5). Furthermore, medications used to treat hyperlipidemia and hypertension prevent colorectal carcinogenesis by attenuating chronic inflammation (6). Similarly, preclinical and clinical studies indicate that non-steroidal antiinflammatory drugs have antitumorigenic activity by inhibiting cyclooxygenases (7). The mechanisms and pathways underlying these effects remain to be identified.

Although a link between inflammation and cancer is appreciated, it is unclear whether increased tumorigenesis results from DIO or instead from independent effects of diet on metabolism and tumorigenesis. Increasing evidence points toward a crucial role of diet in determining tumor growth. Mice fed a high-fat diet (HFD) with reduced vitamin D and calcium show increased weight gain and tumorigenesis compared with counterparts fed a low-fat diet (LFD; ref. 8). Apart from vitamin and nutrient deficiencies, both high-fat and sucrose-rich diets are associated with increased tumorigenesis (9, 10). Mediterranean diets are associated with reduced cancer risk (11). Further, dietary derivatives such as vitamins, β-carotene, resveratrol, and the omega-3/6 fatty acid ratio are directly implicated in maintaining immune homeostasis in the intestine and with protection from colorectal cancer (12, 13). Given the complex relations between diet and obesity as well as between obesity and cancer, identifying the individual contributions of diet and obesity-related metabolic disturbances to increased cancer risk is challenging. Such elucidation could contribute to development of effective ways to manage cancer.

To explore the mechanistic relationships among diet, DIO, and tumorigenesis, we focused on the Min allele of the Apc tumor suppressor gene, an established mouse model of intestinal neoplasia (14). These mice spontaneously develop intestinal polyps.

¹Department of Genetics, Case Western Reserve University, Cleveland, Ohio. ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. ³Pacific Northwest Research Institute, Seattle, Washington. ⁴Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. ⁵Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. ⁶Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

N.A. Berger, J.D. Lambris, and J.H. Nadeau equally supervised this project.

Corresponding Author: J. Nadeau, Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122. Phone: 206-860-6752; Fax: 206-860-6753; E-mail: jnadeau@pnri.org

doi: 10.1158/1541-7786.MCR-16-0153

©2016 American Association for Cancer Research.
in a manner resembling human familial adenomatous polyposis, a condition that carries a 100% risk of developing colorectal cancer (15). Mutations in Apc are observed in 80% of sporadic colorectal cancer cases (15). In parallel, the previously characterized C57BL/6f-Chr2V mouse is rich in omega-6 fatty acids, and the resulting CSS2-V strains (CSS) were purchased from The Jackson Laboratory. CSSs were chosen according to their resistance (A7 and A17) or susceptibility (A2 and A9) to significant diet-induced weight gain (17). Importantly, C5a-induced tumorigenesis occurs independently of obesity or metabolic status. Pharmacological and genetic targeting of C5a receptor (C5aR) prevented diet-induced local and systemic inflammation and significantly reduced polyp burden.

**Materials and Methods**

**Mice**

C57BL/6f (B6, Jackson Laboratory Repository number JR000664) and C57BL/6f-ApcMin/+ (B6.ApcMin/+; JR002020) mice and the corresponding wild-type B6.ApcMin−/− mice, alone or in combination with the selected CSSs with contrasting genetic susceptibility to DIO (17), were able to test the independent effects of diet and obesity on intestinal tumor development.

Here, we show that the chemical composition of dietary fat differentially affects obesity and insulin metabolism. Notably, HFD-induced inflammation from specific dietary fats, rather than obesity or metabolic status, is associated with increased intestinal polyposis. Mechanistically, specific dietary fats activate complement signaling and generate complement fragment C5a, which acts as a key trigger for inflammation and intestinal tumorigenesis. Importantly, C5a-induced tumorigenesis occurs independently of obesity or metabolic status. Pharmacological and genetic targeting of C5a receptor (C5aR) prevented diet-induced local and systemic inflammation and significantly reduced polyp burden.

**Diets**

Diets were obtained from Research Diets. Their composition is detailed in Supplementary Table S1. These diets differed in the source (coconut, corn, or olive oil) and amounts (high or low) of fat. HFDs contained 58% kcal/g from hydrogenated coconut, corn, or olive oil (HFDCorn, HFDComp, or HFDOliver, respectively), while LFDs contained 10.5% kcal/g from the same oils (LFDCorn, LFDComp, or LFDOliver, respectively). The HFD corn diet is rich in saturated fatty acids. HFDcomp is rich in omega-6 polyunsaturated fatty acids (61.5%), similar to Western diets that contain a 25:1 ratio of ω-6:ω-3 fatty acids. HFDolive diet is rich in the monounsaturated fatty acids (71.9%; ref. 20).

**Study design**

From birth to 30 days of age, mice were fed autoclaved Purina 5010 LabDiet, and autoclaved water ad libitum. At 30 days, males were randomized to the HF or LF groups and fed ad libitum until sacrifice after 3 (33 days of age), 30 (60 days of age), or 60 (90 days of age) days on the diet (Fig. 1A). Mice were fasted for 12 to 14 hours and anesthetized with isoflurane prior to blood collection. Whole blood, plasma, and serum samples were collected from the retro-orbital sinus into tubes with or without EDTA. Body weight was measured every other day, and body length was measured at the final time point to calculate body mass index (BMI). At the final time point, mice were euthanized by cervical dislocation, and the epididymal fat pad mass (EFPm) was used as a measure of adiposity. The small and large intestines were immediately removed, flushed with cold PBS, and cut longitudinally. Polyps were counted, and cross-sectional diameter was measured in the epididymal fat pad mass (EFPm). Numbers of mice used in each experiment are also indicated individually with data points in each graph.

**Metabolic and cytokine analysis**

Fasting insulin levels were measured with Merckodia Ultrasensitive Mouse Insulin ELISA. Fasting glucose was measured with an OneTouch Ultra glucometer (Life Scan, Inc.). Homeostatic model assessment of insulin resistance (HOMA-IR; refs. 21, 22) was calculated using fasting insulin and glucose levels [HOMA-IR = fasting insulin (pmol/L)/fasting blood glucose (mmol/L)/22.5]. Leptin, adiponectin, and complement C5a were measured in plasma with ELISA kits from EMD Millipore (leptin and adiponectin) and R&D Systems (C5a).

**Quantitative RT-PCR and protein analysis**

Size-matched polyp and normal tissues were collected from the small intestine of B6.ApcMin−/− mice and B6.ApcMin/+ mice, respectively. Tissues were frozen in Qiagen RLT buffer and RNA extracted with Qiagen RNeasy Mini Kits. Quantitative RT-PCR was done with SYBR Green (Quanta BioSciences) to measure the expression levels of F4/80, IL6, IL1b, TNF, and Myc in adipose or intestinal tissues (see Supplementary Table S2 for primer sequences).
Diet and genetic background determine obesity and insulin resistance. **A**, study design for diet studies. Male mice were maintained on a stock 5010 (gray) diet until 30 days of age (d.o.a.) before being randomly assigned to a HFD (purple) or LFD (blue). Mice remained on a diet study for 3 days (33 d.o.a.), 30 days (60 d.o.a.), or 60 days (90 d.o.a.). Wild-type B6.Apc\(^{+/+}\), A2.Apc\(^{+/+}\), A9.Apc\(^{+/+}\), A7.Apc\(^{+/+}\), and A17.Apc\(^{+/+}\) strains and the equivalent Apc\(^{Min/+}\) (B6.Apc\(^{Min/+}\), A2.Apc\(^{Min/+}\), A9.Apc\(^{Min/+}\), A7.Apc\(^{Min/+}\), and A17.Apc\(^{Min/+}\)) strains were fed the LFD\(_{Coco}\) or HFD\(_{Coco}\) for 60 days. **B**, body weight curves from B6.Apc\(^{+/+}\) and B6.Apc\(^{Min/+}\). Final body weight (C) and HOMA-IR (D) were measured at day 60 of treatment. **E** and **F**, the total number of polyps (E) and polypl mass (F) were measured in the intestine of each mouse at day 60 of treatment. Values represent means ± SEM (n = 5–54 males/group). *, *P < 0.05; **, *P < 0.01; ***, *P < 0.001 in relation to the corresponding LFD-fed group. ****, *P < 0.001, in relation to B6.Apc\(^{Min/+}\) fed HFD.
Tissues for Western blot analysis were immediately submerged in RIPA buffer supplemented with phosphatase and protease inhibitors, frozen in liquid nitrogen, and stored at −80°C. All antibodies (AKT, pAKT, IKK, pIKK, NFκB, p65 NFκB, STAT3, and pSTAT3) were purchased from Cell Signaling Technology and used according to the manufacturer’s instructions. Homogenates from intestinal samples were used to measure intestinal inflammation using R&D Systems and IL1β, IL10, TNFα, VEGF, and IL23 ELISAs and the Milliplex Map Mouse Cytokine/Chemokine Panel from EMD Millipore.

Immunohistochemistry of intestinal tissue

Tissues from the small intestine (ileum) were fixed overnight at 4 °C in 4% paraformaldehyde, pH 7.2, and embedded in paraffin. Cross-sections (5 μm) were de-paraffinized in xylene and rehydrated in serial dilutions of ethanol and 1xPBS. Tissues were blocked in 5% goat serum, 3% BSA, 0.3% Triton X100 in 1x PBS without antigen retrieval. Sections were incubated overnight at 4 °C with a 1:100 dilution of a rabbit polyclonal anti-C3c antibody (ab15980, Abcam) in blocking solution. Sections were washed in 1xPBS and, for secondary detection, incubated with a 1:500 dilution of goat anti-rabbit AlexaFluor 555 (A-21429, Life Technologies) in blocking solution at room temperature for 1.5 hours. After washes in 1xPBS, coverslips were mounted and nuclei counterstained in Vectashield hardset mounting medium with DAPI (H-1500, Vector Laboratories). Images were taken with a Zeiss Axioplan2 and an AxioCam digital camera. Images were processed and layered with Photoshop CS5.

Pharmacological inhibition of C5aR

C5aR was inhibited with the Ac-Phe-[Orn-Pro-(D-Cha)-Trp-Arg] peptide (PMX-53; ref. 23). An inactive peptide containing the same amino acids in a scrambled order served as control. The treatment with PMX-53 or control peptide was initiated concomitantly with the specific LFD or HFD (i.e., 30 days of age). Drugs were diluted in PBS, and subcutaneous injections were administered every other day at 2.0 mg/kg.

Fluorescence-activated cell sorting (FACS) of intestinal immune cells

Lamina propria lymphocytes were isolated using a Percoll gradient. Antibodies for CD11b, CD11c, CD45, and GR1 were purchased from Biolegend and used according to the manufacturer’s instructions. Alternatively, cells were stained with the respective isotypes. All cell preparations showed at least 95% viability as measured with DAPI staining (Life Technologies). Samples were analyzed using the BD LSR II flow cytometer (BD Biosciences) and FCS Express software (v4.0; De Novo Software).

Statistical analysis

Student t tests and one-way analysis of variance (ANOVA) were used to determine statistical significance, which was accepted at the P < 0.05 level after Bonferroni correction for multiple hypotheses testing.

Results

Diet and genetic background determine obesity and insulin resistance

To investigate the mechanisms of DIO-induced inflammation and cancer, we first assessed the effect of diet and genetic background on obesity and glucose homeostasis. Previously characterized CSSs were used to distinguish between diet- versus obesity-induced effects (16, 17). Wild-type B6.Apc+/−/ and C58. Apc+/−/ mice were fed a calorically equivalent diet high or low in hydrogenated coconut oil, HFDcox, or LFD Cox (Supplementary Table S1). After 60 days on HFD versus LFD, B6.Apc+/−/ A2. Apc+/−/ and A9.Apc+/−/ wild-type mice showed increased fasting glucose and insulin with a correspondingly higher insulin resistance index [HOMA-IR] (Fig. 1A–D; Supplementary Table S3). Conversely, A7.Apc+/−/ and A17.Apc+/−/ mice were resistant to DIO and maintained baseline metabolic parameters (Fig. 1C and D; Supplementary Table S3). These results demonstrate the importance of diet and genetic background on development of obesity as well as glucose homeostasis, and validate the use of CSSs that differ in DIO susceptibility as a model for distinguishing the independent contributions of diet and obesity to intestinal tumorigenesis.

Diet, but not obesity or metabolic status, promotes intestinal tumorigenesis

To explore the association between DIO and tumorigenesis, we used mice heterozygous for a mutant form of the Apc tumor suppressor gene (B6.ApcMin+/−) that were fed HFD-Coco, or LFD-Coco. In contrast to B6.Apc+/−/ mice on HFD-Coco, which were ~10% heavier than animals fed the equivalent LFD after 60 days, B6.ApcMin+/−/ mice on HFD-Coco gained weight during the initial 40 days, but then lost weight progressively and were moribund by the 60-day time-point (90 days of age; Fig. 1B and C), consistent with the development of multiple intestinal polyps and cachexia (24).

Total intestinal polyp number and mass were significantly increased in all strains fed the HFD-Coco but not the LFD-Coco after 60 days (Fig. 1E and F; Supplementary Table S3), regardless of obesity or metabolic status (Fig. 1C and D; Supplementary Table S3). While B6.Apc+/−/ mice fed LFD-Coco developed an average of 14 polyps, counts increased 6.6-fold in response to HFD-Coco. Polyp numbers ranged from 6.6 to 27.4 in CSS.Apc+/−/ strains fed LFD-Coco and were 3.3- to 6.6-fold higher in HFD-Coco-fed mice, independent of weight gain or glucose and insulin levels (Fig. 1E; Supplementary Table S3). Similarly, polyp mass increased 8.4- to 20.2-fold in strains fed HFD-Coco compared with LFD-Coco (Fig. 1F; Supplementary Table S3), indicating that dietary fat, rather than obesity and associated metabolic changes, promotes intestinal neoplasia in genomically susceptible B6.ApcMin+/−/ mice.

Although increased polyp number and mass were observed in obesity-susceptible A2. ApcMin+/−/ mice fed HFD-Coco compared with LFD-Coco, these parameters were significantly reduced compared with other strains (Fig. 1E and F). These data suggest presence of a factor on chromosome 2 that modifies intestinal tumorigenesis. Furthermore, an enhanced inflammatory state was observed in the ApcMin+/−/ mice fed the HFD when compared with their LFD counterparts, as evidenced by increased neutrophil counts but were significantly lower in A2. ApcMin+/−/ (Supplementary Fig. S1).

We next investigated the impact of dietary energy content and chemical composition on intestinal neoplasia with diets containing distinct sources of fat (coconut, corn, or olive oil; Supplementary Table S1). As observed in B6.Apc+/−/ mice exposed to HFD-Coco, B6.Apc+/−/ mice fed HFD-Coco were insulin resistant (Fig. 2B; Supplementary Table S4). However, only HFD-Coco, but not HFD-Cox-fed mice displayed increases in FBW, EFPM, and BMI.
Figure 2. Diet, but not obesity or metabolic status, promotes intestinal tumorigenesis. B6.Apc^{Min/+} mice were fed the LFD or HFD with coconut (purple), corn (green), or olive (blue) oil as a source of fat for 60 days. The final body weight (A), HOMA-IR (B), total number of polyps (C) and polyp mass (D) were assessed after day 60 of diet treatment. Values represent means ± SEM (n = 7–54 males/group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 in relation to the equivalent LFD-fed group. ****, P < 0.001 in relation to HFD_{Coco} or HFD_{Corn}-fed groups.
compared with LFD (Fig. 2A; Supplementary Table S4), suggesting that a diet rich in corn oil induces insulin resistance in the absence of obesity. Mice fed HFD_Coco showed significant weight gain without corresponding metabolic changes compared with LFD_Coco, as indicated by increased FBW, BMI, and EFPMA, but normal levels of fasting glucose and insulin (Fig. 2A and B; Supplementary Table S4), in line with previous findings (20). Thus, chemical composition of dietary fat differentially affects obesity and insulin resistance.

Importantly, the various diets also differentially affected intestinal tumorigenesis. Total intestinal polyp number and mass were significantly increased in mice fed HFD_Coco and HFD_Corn compared with corresponding LFD-fed animals (Fig. 2C and D). In contrast, no significant differences in total polyp number or mass were observed in B6.ApcMin/+ fed HFD_Clive versus LFD_Clive (Fig. 2C and D), demonstrating that although a diet rich in olive oil resulted in DIO, it prevented insulin resistance and intestinal neoplasia, suggesting that tumorigenesis may be associated with specific dietary fats rather than obesity.

Similar degrees of tumorigenesis were observed after shorter exposure to a HFD (30 vs. 60 days), independent of fat source (Fig. 2C and D; Supplementary Fig. S2). This dietary effect occurred after a 30-day exposure to dietary fat, prior to significant increases in FBW, BMI, or EFPMA (Supplementary Fig. S2; Supplementary Table S4), indicating that conditions that favor polyposis development are established prior to onset of obesity or insulin resistance.

Intestinal neoplasia is associated with diet-induced inflammation

To identify mechanisms linking dietary fat with intestinal tumorigenesis, we focused on HFD_Coco effects over a 30-day period, before the onset of DIO, metabolic changes, or tumor-induced cachexia. Circulating levels of the proinflammatory cytokines IL6, IL1β, and monocyte chemotactic protein (MCP-1) and the adipose tissue-derived hormone, leptin, were elevated in mice fed HFD_Coco compared with LFD_Coco (Fig. 3A–C and E; cf. ref. 1). Levels of antiinflammatory cytokine IL10 were not affected by diet or strain (Fig. 3D). In contrast, the level of adiponectin, an adipokine that is involved in fatty acid oxidation and has antiinflammatory properties, was reduced in HFD_Coco-fed mice (Fig. 3F).

mRNA expression levels of IL6 and the macrophage marker F4/80 were significantly elevated in adipose tissue from B6.ApcMin/+ in response to HFD_Ccor (Fig. 3G and H). Expression of proinflammatory cytokines II1β, II6, and TNFα was also increased in intestinal tissue of both B6.Apc+/+ and B6.ApcMin/+ mice fed HFD_Ccor, while c-Myc was significantly elevated in response to HFD_Ccor only in B6.ApcMin/+ (Fig. 3I–L), supporting the concept that HFD_Ccor triggers a proinflammatory environment that promotes polyp development.

To examine the influence of diet on early tumor environment, mice were exposed to HFD or LFD for 3 days. Prior to any changes in FBW or HOMA-IR (Fig. 4A and B) after HFD_Ccor exposure, increased intestinal polyp numbers were observed (Fig. 4C and D). Circulating levels of adiponectin were decreased in the HFD-fed mice when compared with the LFD counterparts (Fig. 4F). Remarkably, the short HFD exposure significantly increased IL6, II23, TNFα, and VEGF but not II10 in the intestines of mice fed HFD_Ccor compared with LFD_Ccor (Fig. 4H–L), suggesting that HFD_Ccor rapidly triggers a proinflammatory and proangiogenic environment that promotes polyp development.

Source of dietary fat determines local proinflammatory environment and intestinal polyposis

In light of our observation that HFD_Clive did not promote polyposis in genetically susceptible mice despite DIO (Fig. 2), we evaluated intestinal inflammation in mice fed HFD_Ccor, HFD_Clive or HFD_Coro after a 30-day exposure of wild-type B6.Apc+/+ mice to HFD or the corresponding LFD, levels of VEGF, TNFα, IL23, and IL1β were significantly elevated in mice fed HFD_Ccor and HFD_Clive compared with the LFD (Fig. 5A–D). Although no increase in these inflammatory factors was observed in mice fed HFD_Clive, the antiinflammatory cytokine, IL10, was significantly elevated in HFD_Clive-fed mice (Fig. 5E).

CSS A2.ApcMin/+ [which showed reduced tumorigenesis regardless of dietary exposure or obesity status], was reassessed to explore the link between diet and inflammation. Notably, chromosome 2 in the A/J strain as well as in CSS A2.ApcMin/+ carries a dysfunctional complement component C5 gene (16). C5 is cleaved in response to complement activation, with the subsequent generation of the C5α fragment, an established proinflammatory mediator with a detrimental role in cancer (25–29). This cleavage product signals through the C5a receptor C5aR (30). To test whether dietary fat modulates complement activation, plasma C5a levels were measured in B6.Apc+/+, CSS.Apc+/+, and the corresponding ApcMin/+ strains fed HFD_Ccor or LFD_Ccor for 60 days. All strains, except A2.Apc+/+ and A2.ApcMin−/−, showed a significant increase in plasma C5a in response to HFD_Ccor regardless of obesity status or obesity-associated metabolic changes (Supplementary Fig. S3).

Next, circulating levels of plasma C5a levels were measured in response to the different sources of dietary fat. After 30 days of diet exposure, C5a levels were significantly elevated in both B6.Apc+/+ and B6.ApcMin+−/− strains fed HFD_Ccor or HFD_Clive but not in HFD_Coro when compared with the corresponding LFD-fed mice (Fig. 6A). After a short 3-day exposure to HFD_Ccor, C5a levels were significantly increased in plasma and the intestine (Fig. 4E and G). Additionally, using an antibody that recognizes complement C3 fragment C3c, and the C3c epitope of native C3 and C3c, increased deposition of complement C3 in the normal small intestine was observed in response to HFD_Ccor when compared with LFD_Ccor (Supplementary Fig. S4A–S4D). Specifically, antibody staining accumulated within the lamina propria and along the epithelial basement membrane in the underlying connective tissue. These results are consistent with previous observations that activated complement C3 is deposited along the basement membrane in the inflamed intestinal mucosa of ulcerative colitis (UC) and Crohn disease (CD) patients and that complement C3 is expressed by subepithelial myofibroblasts (SEMF), which are positioned subjacent to IECs along basement membrane, in response to inflammation (31, 32). Curiously, complement C3 also accumulated within polyps of B6.ApcMin+−/− mice fed HFD_Ccor for 30 days (Supplementary Fig. S4E and S4F). Complement C3 localized primarily to the stroma of polyp lesions but was expressed at greatly diminished levels or was absent in the stroma surrounding normal epithelial cells in deep crypts under polyp lesions and positioned the greatest distance from the intestinal lumen. These results indicate that interactions with specific dietary fats trigger C3 activation and C5α generation shortly after HFD exposure.
Complement C5a mediates diet-induced inflammation and intestinal neoplasia

The link between HFD-induced complement activation and intestinal tumorigenesis was confirmed with a genetically engineered knockout mutation in the C3 complement component (C3) gene that was backcrossed onto the B6.Apc\(^+/+\) background. Absent (homozygotes) or reduced (heterozygotes) C3 levels, which is normally essential for complement activation (33), resulted in reduced polyp number and mass in the intestine of HFD\(_{C5a}\)-fed mice (Supplementary Fig. S5). Similarly, diminished tumorigenesis was observed in C5aR\(^{-/-}\) mice on a B6.Apc\(^{Min/+}\) background fed HFD\(_{C5a}\) (Fig. 6B and C), supporting a role for the C3–C5a–C5aR axis in diet-induced intestinal neoplasia. In addition, pharmacological targeting of C5aR with the antagonist peptide PMX-53 (23), but not an inactive control peptide, resulted in a significant reduction in polyp number and mass resulting from HFD exposure (Fig. 6B and C; Supplementary Table S5). Complement deficiency did not influence body weight or glucose and insulin levels in mice fed the HFD\(_{C5a}\) for 30 days (Supplementary Table S5). Further, genetic or pharmacological inhibition of C5aR did not significantly reduce polyp number or mass in males fed LFD\(_{C5a}\) (Supplementary Table S5), supporting the notion that C5a specifically mediates HFD-induced inflammation.
Mechanistically, genetic and pharmacologic inhibition of C5aR signaling reduced HFD-induced inflammation as indicated by reduced levels of intestinal VEGF, TNFα, and IL23 (Fig. 6D–I). In addition, abrogation of C5aR signaling with PMX-53 inhibited AKT-NFκB signaling, which has been implicated in inflammation and cancer (34). Whereas increased levels of phosphorylated AKT, IKK, and NFκB were observed in polyp tissue from B6.ApcΔMin/+ mice fed HFD°C5a, as compared with normal B6.ApcΔ−/− tissue, activation was attenuated in mice treated with PMX-53 but not in the control peptide (Fig. 6M). Furthermore, pharmacological targeting of C5aR resulted in reduced mRNA expression levels of IL1β and c-Myc in polyp tissue (Fig. 6J and K), and prevented infiltration of inflammatory neutrophils to the lamina propria (Fig. 6L), which has been implicated as a key inflammatory trigger in DIO response (35).

Discussion

Here, we show that complement C5a-induced inflammation promotes intestinal tumorigenesis. Complement signaling modulates various pathophysiological processes and has been previously implicated in tumorigenesis (33). Recent findings indicate that complement activation in the tumor microenvironment leads to tumor growth and metastasis. In vivo models using breast, lung and colon cancer cell lines showed that C5aR-mediated signaling creates a microenvironment that promotes growth through recruitment of myeloid-derived suppressor cells (MDSC) and inhibition of antitumor immune responses mediated by CD8+ and CD4+ T cells (25, 27–29, 36). In addition, C5a-induced inflammation is associated with promotion of angiogenesis and tumor progression. In the absence of C3 or C5aR-mediated signals, mice genetically susceptible to ovarian cancer develop small, poorly vascularized tumors. While MDSCs do not seem to play a role in this model, complement activation is associated with increased tumorigenesis as indicated by elevated regulatory T-cell numbers and increased VEGF-induced angiogenesis (37). Complement activation also promotes colitis-associated carcinogenesis via induction of proinflammatory IL1β and IL17 by bone marrow-derived neutrophils (38). In addition to creating a proangiogenic and protumorigenic microenvironment, C3α and C5a derived from tumor cells have an autocrine effect on tumor proliferation via activation of the PI3K/AKT signaling pathway (26). Such findings agree with our observations that the C5aR antagonist PMX-53 prevents activation of AKT/IKK/NFκB following HFD°C5a exposure (Fig. 6M). Additionally, deficiency of PTX3 has been associated with increased susceptibility to mesenchymal and epithelial carcinogenesis due to poor regulation of complement activation and consequent inflammation (39). Further, development of hepatocellular carcinoma mediated by HFD-induced inflammation involved c-Myc and NFκB signaling pathways in genetically C5-sufficient (C57BL/6) but not in C5-deficient (A/J) mice (40), pointing to complement activation as a link between DIO and cancer. Finally, recent reports suggest that C3αR- and C5αR-mediated signaling modulates neutrophil and CD8+ T-cell function with consequent increased tumorigenesis (41–43).

Obesity has become a major public health concern because of its association with medical conditions such as hypertension, diabetes, cardiovascular disease, and certain cancers (44). Although mutations in genes such as leptin, leptin receptor, and melanocortin-4 receptor affect satiety control, glucose homeostasis and energy metabolism, common obesity is considered a multifactorial disorder controlled by multiple genes combined with environment factors, such as diet, physical activity, and intestinal microbiota (45, 46). Given the complexity involved in
Figure 5.
Source of dietary fat determines local proinflammatory environment and intestinal polyposis. B6.Apc\(^{++/-}\) and B6.Apc\(^{Min/-}\) mice were fed diets supplemented with coconut (purple), corn (green), or olive (blue) oil for 30 days. Levels of anti- and proinflammatory mediators implicated in inflammation and cancer such as VEGF (A), TNF\(\alpha\) (B), IL23 (C), IL1\(\beta\) (D), and IL10 (E) were measured in intestinal tissue at day 30 of treatment. Values represent means \(\pm\) SEM (\(n = 3\)–5 males/group). *, \(P < 0.05\); **, \(P < 0.01\) in relation to the same strain fed the LFD\(_{Coco}\). #, \(P < 0.05\); ##, \(P < 0.01\) in relation to the same strain fed the corresponding LFD\(_{Coco}\) or HFD\(_{Coco}\).
Clustering levels of the complement activation fragment C5a were measured in the plasma at day 30 of treatment (A). B–F, B6.Apc\textsuperscript{Min/+} (C5aR\textsuperscript{-/-}; Min/+), and the complement-deficient C5aR\textsuperscript{-/-}; Apc\textsuperscript{Min/+} (C5aR\textsuperscript{-/-}; Min/+; Apc\textsuperscript{-/-}; Min/+), strains were fed HFD\textsubscript{corn} or LFD\textsubscript{corn} for 30 days. The total number of polyps (B) and poly mass (C) were measured in the intestine of each mouse at day 30 of treatment (n = 5–20/group). Intestinal inflammation was measured in mice genetically deficient in C5aR (D–F). Protein levels of VEGF (D), TNF\alpha (E), and IL23 (F) were measured in the intestine (n = 3–5/group) B6.Apc\textsuperscript{-/-} and B6.Apc\textsuperscript{Min/+} mice were fed HFD\textsubscript{corn} for 30 days, and concomitantly treated with the C5aR antagonist peptide (PMX53) or a scrambled inactive peptide (control; 2 mg/kg s.c.) every other day (B and C). D and E, intestinal inflammation was measured in males treated with PMX53 or control inhibitor (n = 3–5). Total polyp number (B) and polyp mass (C) were measured. Protein levels of VEGF (G), TNF\alpha (H), and IL23 (I) and expression of IL1\beta (J) and Myc (K) were measured in the intestine of males treated with PMX53 or the control inhibitor (n = 3–6/group). L, the percentage of viable CD11b\textsuperscript{hi}/CD11c\textsuperscript{-/-} neutrophils was measured with flow cytometry in the intestinal lamina propria of B6.Apc\textsuperscript{-/-} and B6.Apc\textsuperscript{Min/+} males treated with PMX53 or the control peptide (n = 4/group). Levels of phosphorylated AKT (pS473), IKK (pS176), and NF\kappaB (pS536) were assessed with Western blotting (M) in polytissue of B6.Apc\textsuperscript{Min/+} males or normal intestinal tissue of B6.Apc\textsuperscript{-/-} males treated with PMX53 or the control peptide. Levels of AKT and NF\kappaB were measured as a control for the protein amount loaded. Results are representative of 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with same strain fed corresponding LFD. $, P < 0.05; $$, P < 0.01; $$$, P < 0.001 compared with B6.Apc\textsuperscript{-/-} or B6.Apc\textsuperscript{Min/+} fed the same diet.

Figure 6. Complement C5a mediates diet-induced inflammation and intestinal neoplasia. B6.Apc\textsuperscript{-/-} and B6.Apc\textsuperscript{Min/+} mice were fed the LFD or HFD with coconut (purple), corn (green), or olive oil (blue) as a source of fat for 30 days. Circulating levels of the complement activation fragment C5a were measured in the plasma at day 30 of treatment (A). B–F, B6.Apc\textsuperscript{Min/+} (C5aR\textsuperscript{-/-}; Min/+), and the complement-deficient C5aR\textsuperscript{-/-}; Apc\textsuperscript{Min/+} (C5aR\textsuperscript{-/-}; Min/+; Apc\textsuperscript{-/-}; Min/+), strains were fed HFD\textsubscript{corn} or LFD\textsubscript{corn} for 30 days. The total number of polyps (B) and poly mass (C) were measured in the intestine of each mouse at day 30 of treatment (n = 5–20/group). Intestinal inflammation was measured in mice genetically deficient in C5aR (D–F). Protein levels of VEGF (D), TNF\alpha (E), and IL23 (F) were measured in the intestine of males treated with PMX53 or the control inhibitor (n = 3–5). Total polyp number (B) and polyp mass (C) were measured. Protein levels of VEGF (G), TNF\alpha (H), and IL23 (I) and expression of IL1\beta (J) and Myc (K) were measured in the intestine of males treated with PMX53 or the control inhibitor (n = 3–6/group). L, the percentage of viable CD11b\textsuperscript{hi}/CD11c\textsuperscript{-/-} neutrophils was measured with flow cytometry in the intestinal lamina propria of B6.Apc\textsuperscript{-/-} and B6.Apc\textsuperscript{Min/+} males treated with PMX53 or the control peptide (n = 4/group). Levels of phosphorylated AKT (pS473), IKK (pS176), and NF\kappaB (pS536) were assessed with Western blotting (M) in polytissue of B6.Apc\textsuperscript{Min/+} males or normal intestinal tissue of B6.Apc\textsuperscript{-/-} males treated with PMX53 or the control peptide. Levels of AKT and NF\kappaB were measured as a control for the protein amount loaded. Results are representative of 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with same strain fed corresponding LFD. $, P < 0.05; $$, P < 0.01; $$$, P < 0.001 compared with B6.Apc\textsuperscript{-/-} or B6.Apc\textsuperscript{Min/+} fed the same diet.

Clinical studies to evaluate obesity-related diseases in humans, mouse strains are essential for studying the physiology of DIO and metabolic syndrome (47, 48). CSSs in particular are a valuable paradigm for disentangling the complex relations among diet, obesity, and metabolic status (Fig. 1C and D; refs. 16, 17). These CSSs together with cancer promoting genetic models such as Apc\textsuperscript{Min/+} (49) are genetically defined, reproducible experimental model system that can be used to explore mechanisms underlying interactions among diet, metabolism, and inflammation on tumorigenesis.

Extensive epidemiological research has recently established an association between obesity and increased risk of cancer (40, 50, 51). Obesity is considered a leading environmental risk for colorectal cancer and obesity-induced inflammation has been correlated to various stages of cancer progression, including cellular transformation, promotion, survival, invasion, angiogenesis and metastasis (51). Obesity results in the accumulation of large adipocytes that upon necrosis recruit macrophages that secrete proinflammatory cytokines and are implicated in the process of insulin resistance. In addition to the influence of diet on tumorigenesis in the GI tract, HFDs promote tumors with earlier appearance, greater frequency, accelerated growth, larger size, and in some cases more frequent metastasis (50). For example, HFD has been shown to lead to
hapatocellular cancer in C57BL/6J mice (40) and feeding a Western type diet, enriched in fat and cholesterol, accelerates tumor progression in mice with an autochthonous model of prostate cancer (52). Further demonstration of diet on tumorigenesis, outside the intestine, is provided by demonstration that a high fat, lard-based diet, fed to obesity-resistant BALB/c mice promoted faster tumor growth and increased metastasis in mice orthotopically inoculated with syngeneic mammary carcinoma cells (53).

In this study, specific HFDs induced upregulation of the proinflammatory cytokines MCP-1, IL-1β, IL-6, IL-23, TNFα, and VEGF in adipose tissue, intestine and blood, which correlated with increased tumorigenesis (Figs. 3–6). The tumor microenvironment favors a collaboration between malignant and immune cells as well as proinflammatory mediators secreted by tumor-infiltrating lymphocytes that promote cell proliferation and angiogenesis (54, 55). Increased levels of proinflammatory cytokines and angiogenic factors are found in serum and adipose tissue of colorectal cancer patients and are correlated with poor survival (54). Interestingly, lean mice fed HFD presented increased inflammation and tumorigenesis, indicating that the HFD itself and not obesity or the related metabolic status determines the local environment that favors tumor growth. It has recently been shown that HFD promotes tumorigenesis in the small intestine of genetically susceptible KrasG12DInt mice, independent of obesity, as a consequence of a shift in gut microbiota composition and a decrease in Paneth-cell–mediated antimicrobial host defense (10). Dietary interventions can significantly influence gut microbiota, thereby affecting disease outcomes. In this study, HFDs composed of specific dietary fats induced complement activation with consequent release of the proinflammatory C5a fragment as soon as after 3 days of diet exposure, suggesting that complement activation may occur prior to the microbiota shift and may influence the composition of intestinal bacteria given the anti-inflammatory properties of the complement component system (30, 33). Indeed, inhibition of C5aR-mediated signaling has been previously shown to alter the composition and diversity of skin microbiota along with the proinflammatory profile (56).

Adipose tissue is a relevant source of complement proteins, including C3, Factor B, and properdin, that are required for activation of the alternative pathway. Local complement activation and consequent production of C5a regulate infiltration of proinflammatory macrophages into adipose tissue and promote insulin resistance (57). This study showed that specific HFDs induced complement activation, adding to the current understanding on the local role of complement in adipose tissue. To our knowledge, only one in vitro but no in vivo study has demonstrated complement activation by a specific dietary component (gluten; ref. 58). Clearly, further investigation is needed to dissect the precise fatty acids responsible for complement activation. Nevertheless, such observations open new avenues for research on diet-induced inflammatory diseases and places complement as a key target for therapeutic intervention in such conditions.

Apart from complement, fatty acids are involved in immunological processes via direct activation of immune cells and release of proinflammatory mediators (59). Whereas saturated fatty acids contribute to promoting inflammation, unsaturated fatty acids show both pro- and antiinflammatory properties and the balance between omega-3 and omega-6 is considered critical for maintenance of healthy levels of fat (12). Reduced levels of complement activation, inflammatory cytokines, and tumorigenesis were observed in mice fed HFDolive despite similar levels of obesity compared with those fed HFDcorn (Figs. 2, 5, 6A). Olive oil, which is rich in the unsaturated oleic acid, has antioxidant properties and, together with other components such as phenolic compounds, induces antiproliferative and antiinflammatory responses (20). Together, we found that certain HFDs activate complement, regardless of DIO, and generate C5a, which in turn promotes a proinflammatory environment by triggering signaling pathways that control expression of proto-oncogenes and release of

Figure 7.
Molecular mechanisms determining HFD-induced intestinal polyp progression. Diets high in specific dietary fats induce an inflammatory environment in the intestine that promotes intestinal tumorigenesis in genetically susceptible APCmin mice, independent of obesity and related metabolic conditions. HFD containing coconut or corn oil as a source of saturated fat induce complement activation with subsequent release of C5a. C5a in turn induces the infiltration of inflammatory neutrophils to the intestinal lamina propria and activate the AKT/IKK/NFκB signaling pathway in intestinal cells with consequent production of proinflammatory mediators such as IL-1β, IL-6, TNFα, and the proto-oncogene c-myc. Conversely, mice fed a HFD containing olive oil as a source of fat gained significant body weight, but did not promote a proinflammatory environment or development of polyps in the intestine.
inflammatory mediators, consequently favoring formation of intestinal polyps in genetically susceptible mice (Fig. 7). Importantly, three observations were made that indicate dissociation between DIO and high dietary fat in tumor development: increased intestinal tumorigenesis in both DIO-susceptible and DIO-resistant CSS mice (Fig. 1C–F), increased polyp numbers in lean mice after only 3 days of HFD exposure (Fig. 4A–D), and lack of tumor progression in obese HFD_{Olive}-fed mice (Fig. 2). As such, these results show that HFD-induced complement activation and C5a generation promote inflammation and intestinal tumorigenesis prior to the onset of obesity. Given that HFD-induced complement activation is an upstream event and is crucial for the establishment of inflammation, and given the beneficial effects of anti-inflammatory therapies in cancer (7), these data point to complement-targeted therapeutics (60) as a potentially powerful means of preventing diet-induced neoplasia.

Disclosure of Potential Conflicts of Interest

S.K. Doerner, N.A. Berger, J.D. Lambris, and J.H. Nadeau are co-investigators in a patent application titled “A method to treat polyp formation.” No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S.K. Doerner, N.A. Berger, J.D. Lambris, and J.H. Nadeau

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.K. Doerner, E.S. Leung, J.S. Ko, J.D. Heaney, N.A. Berger, and J.H. Nadeau

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.K. Doerner, E.S. Reis, J.D. Heaney, N.A. Berger, and J.H. Nadeau

Writing, review, and/or revision of the manuscript: S.K. Doerner, E.S. Reis, J.D. Heaney, N.A. Berger, J.D. Lambris, and J.H. Nadeau

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.K. Doerner, N.A. Berger, and J.H. Nadeau

Study supervision: N.A. Berger, J.D. Lambris, and J.H. Nadeau

Other (e.g., collection, data, or analysis): E.S. Leung, J.S. Ko

References


Acknowledgments

We thank David A. DeSantis and Carmen Fiuza-Luces for technical assistance. This work was supported by the Transdisciplinary Research in Energy Balance and Cancer Grant #U54 CA166867 to N.A. Berger and J.H. Nadeau, AI030040 and AI068730 to J.D. Lambris and P40 RR012305 to J.H. Nadeau and N.A. Berger.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 2, 2016; revised July 21, 2016; accepted July 24, 2016; published OnlineFirst August 17, 2016.

Doerner et al.


